Moderna rebounded approximately days before the release of detailed Phase cancer therapy data 11%

Article

Cancer therapy sparks a near-285%gain,Moderna up again over the past days 11%

BlockBeats News,October 21，Moderna（MRNA) rebounded consecutively ahead of the release of key cancer therapy data. It rose 4.07%and 6.69%respectively over the past U.S. trading days, for a cumulative gain of approximately 11.04%, most recently closing at 242.08 USD, with an intraday high of 243.98 USD. The corresponding Hyperliquid contract is quoted at 241.07 USD，24, up approximately 5.71%。

hours. A key catalyst for this rebound is the imminent release of detailed Phase data for the personalized mRNA cancer therapy intismeran autogene, jointly developed by Moderna and Merck. According to the companies' schedule, at October 24 on 22: 30, the parties will present, at the European Society for Medical Oncology (ESMO) Congress,INTerpath-001 Phase study results for high-risk melanoma, and will hold an investor event on October 25 at 01: 00.

This release is the detailed validation the market has awaited following previously positive results. The companies announced on August 19 that the therapy in combination with Keytruda met the primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS). This weekend, investors will further assess the magnitude of benefit, safety, and implications for research in other cancer types.

Since August 18, the close on the trading day before the above positive results were announced,MRNA has risen cumulatively by approximately 284.5%, with its share price already substantially reflecting optimistic expectations for its oncology pipeline. Although the biotechnology sector has performed strongly overall,MRNA still fell 7.82%in a single day last Friday, and this week's -day rebound also includes a recovery from the prior pullback.

While Wall Street institutions continue to raise valuations, they are not unanimously chasing the rally. Bank of America recently raised Moderna's price target from 200 USD to 220 USD, while maintaining a "Neutral" rating, believing that the focus of the ESMO Congress will be the actual magnitude of benefit from the combination therapy and whether it can inform subsequent studies in renal cancer, bladder cancer, and other indications. The revised 220 USD price target remains below MRNA's latest 242.08 USD closing price by approximately 9.1%。

. As the share price continues to approach highs, a short position of approximately 4520000 USD is nearing liquidation.

According to TradingBeats monitoring, a whale address beginning with 0x4e23 is currently short approximately 10 contracts of 18700 using MRNA x isolated leverage, with a position value of approximately 4518000 USD, an average entry price of 237.04 USD, and an unrealized loss of approximately 75500 USD. The estimated liquidation price for this position is 248.37 USD, only approximately 3.03%above the current mark price, a difference of approximately 7.30 USD。